KBRA releases research examining the differences between asset-backed securities (ABS) and commercial mortgage-backed securities (CMBS) for data center transactions, providing insight into how ...

A research team led by Professors Park Seob-ri and Kim Nam-hoo of orthopedics at Yonsei University Yongin Severance Hospital ...

A clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa and published in the New England ...

today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus entrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be ...

New research - led by the University of Portsmouth ... I spent some years working at a hospital in the US trying to compare permeability data measured in people and animals with computer-simulated ...

Google's AI Mode, the experimental Google Search feature that lets users ask complex, multi-part questions via an AI interface, will roll out to everyone ...

Provide specific products and services to you, such as portfolio management or data aggregation ... of our people and exacting analysis of our research processes. Our authors can publish views ...

Results from the International Comparison Program (ICP) 2021 cycle include data for the reference year 2021, revised data for the reference year 2017, purchasing power parity (PPP) time series for ...

Have you ever wondered how your canton compares to the others? Explore and compare data across the 26 cantons – either by time series or single year comparison, single indicator or theme. Are you ...

Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC ...